Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β3‐adrenoceptor agonist (Mirabegron) for overactive bladder (OAB)

Publisher： John Wiley & Sons Inc

E-ISSN： 1464-410x|115|1|32-40

ISSN： 1464-4096

Source： BJU INTERNATIONAL, Vol.115, Iss.1, 2015-01, pp. : 32-40

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and Safety of the Selective β3‐Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Finding Study

By  

LUTS, Vol. 7, Iss. 2, 2015-05 ,pp. : 84-92

John Wiley & Sons Inc

Access to resources Recommend Favorite

Results of a randomized, double‐blind, parallel‐group, placebo‐ and active‐controlled, multicenter study of mirabegron, a β3‐adrenoceptor agonist, in patients with overactive bladder in Asia

By  

NEUROUROLOGY AND URODYNAMICS, Vol. 34, Iss. 7, 2015-09 ,pp. : 685-692

John Wiley & Sons Inc

Access to resources Recommend Favorite

Video‐urodynamic effects of mirabegron, a β3‐adrenoceptor agonist, in patients with low‐compliance bladder

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 919-8172, Iss. 10, 2015-10 ,pp. : 956-961

John Wiley & Sons Inc

Access to resources Recommend Favorite

Video‐urodynamic effects of mirabegron, a β3‐adrenoceptor agonist, in patients with low‐compliance bladder

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 10, 2015-10 ,pp. : 956-961

John Wiley & Sons Inc

Access to resources Recommend Favorite

The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double‐blind, placebo‐controlled phase 2 study

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 2, 2015-02 ,pp. : 242-250

John Wiley & Sons Inc

Access to resources Recommend Favorite